- ►shouxi.net JK Wolford, KA Yeatts, SK Dhanjal, MH … - Diabetes, 2005 - Am Diabetes Assoc Thiazolidinediones (TZDs) are peroxisome proliferator–activated receptor-γ
(PPARG) agonists used to treat type 2 diabetes. TZDs can also be used to reduce
rates of type 2 diabetes in at-risk individuals. However, a large fraction ... Cited by 31 - Related articles - BL Direct - All 5 versions
ES Kang, SY Park, HJ Kim, CS Kim, CW Ahn, … - Clinical pharmacology and therapeutics, 2005 - 134.68.189.85 Objective: The aim of this study was to examine the effects of the Pro12Ala
polymorphism of the peroxisome proliferator–activated receptor (PPAR) 2 gene
on the response to rosiglitazone in patients with type 2 diabetes mellitus. ... Cited by 32 - Related articles - View as HTML - All 8 versions
- Free from Publisher M Blüher, G Lübben, R Paschke - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 131 patients were treated in an
open-label, randomized, multicenter study with pioglitazone (45 mg od) during a
course of ≥26 weeks. Response to the pioglitazone therapy was defined by ... Cited by 43 - Related articles - BL Direct - All 5 versions
- ►endojournals.org JC Florez, KA Jablonski, MW Sun, N Bayley, … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: The common P12A polymorphism in PPARG (a target for thiazolidinedione
medications) has been consistently associated with type 2 diabetes. ...
Objective: We examined whether PPARG P12A affects progression from impaired ... Cited by 41 - Related articles - BL Direct - All 7 versions
- ►endojournals.org G Sesti, E Laratta, M Cardellini, F Andreozzi, … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Several studies suggest that genetic factors may play a role in the
different responses to antidiabetic therapy; however, conclusive evidence is
still lacking. ... Objective: The objective of the study was to ... Cited by 26 - Related articles - BL Direct - All 3 versions
- ►diabetesjournals.org S Snitker, RM Watanabe, I Ani, AH Xiang, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—The mean changes in S i in the bottom, middle, and top tertiles of S i
response were −0.21 ± 0.57, 0.91 ± 0.26, and 2.58 ± 1.32 min −1 per
μU/ml · 10 −4 , respectively. Frequencies of the Ala/− genotype were ... Cited by 40 - Related articles - BL Direct - All 5 versions
F Mousavinasab, T Tähtinen, J Jokelainen, P … - Endocrine, 2005 - Springer Received May 24, 2005; Revised June 29, 2005; Accepted June 29, 2005. Author to
whom all correspondence and reprint requests should be addressed: Firoozeh
Mousavinasab, Department of Public Health Science and General Practice, ... Cited by 15 - Related articles - BL Direct - All 3 versions
- ►endojournals.org L Hansen, CT Ekstrom, R Tabanera y … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Activation of peroxisome proliferator-activated receptors (PPARs)- by
thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPAR / agonists
(pargluva, ragaglitazar) is a widely used pharmacological principle to ... Cited by 18 - Related articles - BL Direct - All 2 versions
R BUZZETTI, A PETRONE, AM CAIAZZO, I … - Pediatric Research, 2005 - journals.lww.com Several genetic variants of peroxisome proliferator-activated receptor-2
(PPAR-2), a molecule known to be involved in transcription of target genes, have
been identified. Pro12Ala, a missense mutation in exon 2 of the gene, is ... Cited by 19 - Related articles - All 4 versions
C Foucher, S Rattier, DM Flavell, PJ Talmud, … - Pharmacogenetics and Genomics, 2004 - journals.lww.com Objective: The association between polymorphisms in candidate genes related to
lipoprotein metabolism and the reduction in plasma triglyceride (TG) in response
to fenofibrate treatment was evaluated in subjects with type 2 diabetes ... Cited by 19 - Related articles - All 6 versions
